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To	  address	  emerging	  infections,	  we	  must	  invest	  in	  enduring	  systems:	  	  
The	  kinetics	  and	  dynamics	  of	  health	  systems	  strengthening	  
	   Clinical	  pharmacology	  uses	  foundational	  principles	  of	  pharmacokinetics	  (PK)	  and	  pharmacodynamics	  (PD)	  to	  address	  medication	  use	  spanning	  a	  continuum	  from	  molecules	  to	  the	  masses.	  In	  the	  realm	  of	  infectious	  diseases,	  PK/PD	  attributes	  are	  considered	  especially	  important,	  because	  sub	  therapeutic	  dosing	  of	  antibiotics	  has	  been	  associated	  with	  poorer	  clinical	  outcomes	  in	  patients	  and	  increased	  incidences	  of	  drug	  resistance	  in	  populations.	  	  In	  consideration	  of	  these	  PK/PD	  principles,	  we	  will	  describe	  the	  analogous	  relationship	  between	  health	  systems	  strengthening,	  including	  for	  educating	  healthcare	  providers	  about	  emerging	  infections,	  and	  the	  tenets	  of	  therapeutic	  drug	  monitoring.	  	  	  
Worldwide,	  the	  populations	  bearing	  the	  greatest	  burden	  of	  emerging	  infectious	  diseases	  live	  in	  low-­‐	  and	  middle-­‐income	  countries	  (LMICs),	  where	  the	  typical	  tools	  for	  addressing	  these	  -­‐	  such	  as	  preparedness	  plans,	  stockpiles	  of	  drugs	  and	  vaccines,	  and	  the	  health	  professionals	  to	  initiate	  them	  -­‐	  are	  lacking1.	  	  	  Indeed,	  responses	  to	  outbreaks	  can	  be	  described	  as	  having	  a	  narrow	  therapeutic	  range	  where	  a	  small	  misstep	  can	  lead	  to	  catastrophic	  consequences	  for	  the	  affected	  populations.	  This	  phenomenon	  is	  especially	  pronounced	  when	  local	  health	  systems	  are	  weakened	  by	  inadequate	  infrastructure,	  underdeveloped	  processes,	  and	  critical	  shortages	  of	  skilled	  health	  professionals.	  In	  times	  of	  acute	  crisis,	  these	  system	  challenges	  result	  in	  devastating	  effects	  locally,	  which	  then	  affect	  the	  wider	  world	  indirectly	  through	  hysteria,	  isolationism,	  stigmatization,	  and	  economic	  
	   3	  
destabilization.	  And	  with	  people	  traveling	  more	  frequently	  and	  over	  greater	  distances	  than	  in	  the	  past,	  health	  systems	  deficits	  can	  result	  directly	  in	  global	  spread	  of	  disease.	  Experts	  suggest	  that	  the	  battle	  against	  emerging	  infectious	  diseases	  will	  continue	  for	  some	  time,	  so	  it	  is	  important	  that	  we	  find	  a	  model	  to	  protect	  against	  future	  threats1.	  	  	  
Reflection	  on	  global	  planning	  for	  and	  responses	  to	  emerging	  infections	  provides	  important	  lessons	  of	  how	  to	  improve	  this	  therapeutic	  regimen.	  It	  is	  clear	  that	  failure	  to	  acknowledge	  disease	  severity,	  delay	  in	  response,	  and	  misaligned	  type	  of	  response	  leads	  to	  worsening	  of	  the	  epidemic.	  	  This	  combination	  initiates	  a	  dose-­‐response	  cycle	  that	  exists	  regardless	  of	  the	  infecting	  organism	  and	  is	  difficult	  to	  alter.	  	  A	  haunting	  recent	  example	  of	  this	  comes	  from	  the	  Ebola	  epidemic.	  Despite	  multiple	  outbreaks	  since	  1976,	  response	  to	  the	  2014	  outbreak	  was	  delayed,	  claiming	  more	  than	  1000	  lives	  before	  WHO	  declared	  it	  an	  international	  crisis.	  With	  malaria,	  although	  a	  global	  eradication	  campaign	  was	  initiated	  in	  the	  mid	  1990s,	  it	  was	  abandoned	  before	  the	  control	  infrastructure	  was	  strong,	  leading	  to	  a	  subsequent	  rise	  in	  morbidity	  and	  mortality.	  	  Despite	  decades	  of	  devastatingly	  high	  mortality	  from	  HIV/AIDS	  in	  Sub-­‐Saharan	  Africa,	  it	  was	  not	  until	  2004	  when	  systems	  initiatives	  enabled	  developing	  countries	  to	  reliably	  access	  highly	  active	  antiretroviral	  therapy	  (HAART).	  	  And	  failure	  to	  sustain	  initial	  reductions	  in	  tuberculosis	  infection	  rates	  has	  led	  to	  more	  resistant	  disease	  today.	  	  The	  timelines,	  responses,	  and	  impacts	  for	  representative	  emerging	  and	  re-­‐emerging	  epidemics	  in	  Sub-­‐Saharan	  Africa	  can	  be	  seen	  in	  Figure	  1.	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To	  treat	  these	  challenges	  locally	  and	  to	  vaccinate	  against	  future	  risk	  globally,	  some	  have	  called	  for	  responses	  that	  are	  better	  aligned	  with	  local	  needs,	  	  ie,	  a	  greater	  focus	  on	  surveillance,	  health	  systems	  strengthening,	  and	  training	  of	  health	  professionals	  from	  low	  resource	  settings2,3.	  	  Essentially,	  the	  goal	  is	  to	  employ	  strategies	  that	  maximize	  total	  exposure	  to	  therapeutic	  interventions	  over	  time	  in	  order	  to	  build	  local	  capacity,	  infrastructure,	  and	  systems	  to	  address	  emerging	  infections.	  	  	  This	  strategy	  can	  be	  interpreted	  much	  like	  the	  area	  under	  the	  curve	  (AUC)	  calculation	  is	  used	  for	  drug	  dosing	  and	  monitoring.	  	  
The	  prevailing	  model	  for	  international	  development	  is	  essentially	  bolus	  injections	  of	  reactive	  funding,	  external	  technical	  assistance,	  and	  uncoordinated	  training	  efforts	  as	  brokered	  by	  aid	  organizations	  such	  as	  the	  Global	  Fund,	  the	  World	  Bank,	  and	  USAID4.	  The	  effects	  of	  this	  treatment	  are	  rapid	  but	  the	  half-­‐life	  is	  short;	  dissipating	  quickly	  once	  the	  bolus	  is	  discontinued.	  In	  contrast,	  a	  continuous	  infusion	  of	  a	  lower	  dose	  of	  the	  treatment	  is	  more	  likely	  to	  achieve	  steady	  state	  (stable	  healthcare	  systems)	  by	  allowing	  effects	  to	  build	  at	  a	  pace	  that	  is	  locally	  responsive4.	  In	  the	  short	  term,	  however,	  this	  regimen	  produces	  a	  lower	  peak	  concentration	  for	  addressing	  the	  crisis	  at	  hand.	  Combination	  dosing	  –	  including	  both	  loading	  and	  maintenance	  drips	  –	  leads	  to	  the	  greatest	  improvement	  in	  AUC	  by	  yielding	  not	  only	  the	  immediate	  response	  required	  to	  address	  emerging	  infectious	  diseases	  but	  also	  the	  capacity	  to	  sustain	  these	  gains	  in	  the	  face	  of	  future	  threats.	  Once	  the	  health	  system	  achieves	  steady	  state,	  we	  predict	  there	  will	  also	  be	  spillover	  gains	  for	  addressing	  other	  health	  challenges,	  similar	  to	  those	  seen	  with	  the	  transition	  of	  HIV/AIDS	  infrastructure	  to	  address	  additional	  chronic	  diseases	  beyond	  HIV/AIDS	  in	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Sub-­‐Saharan	  Africa.	  Figure	  2	  illustrates	  how	  principles	  of	  pharmacokinetics/pharmacodynamics	  can	  be	  applied	  to	  health	  systems	  strengthening	  for	  emerging	  infectious	  diseases.	  
One	  national	  example	  of	  this	  combination	  dosing	  approach	  is	  the	  US	  partnership	  with	  the	  government	  of	  Rwanda	  to	  create	  a	  Human	  Resources	  for	  Health	  (HRH)	  model	  which	  will	  train	  thousands	  of	  new	  healthcare	  providers	  locally	  within	  seven	  years5.	  	  Of	  particular	  importance	  in	  Rwanda’s	  ambitious	  plan	  is	  its	  focus	  on	  interprofessionalism	  as	  a	  way	  of	  highlighting	  the	  strengths	  of	  different	  fields	  in	  order	  to	  fill	  gaps	  in	  quality	  of	  care.	  Lessons	  learned	  from	  this	  initiative	  could	  also	  benefit	  the	  struggling	  US	  health	  system3.	  	  Parallel	  to	  this	  project	  is	  an	  expansion	  of	  and	  support	  for	  new	  cadres,	  such	  as	  community	  health	  workers,	  to	  address	  many	  healthcare	  needs	  without	  the	  lengthy	  periods	  of	  additional	  training	  associated	  with	  physician	  specialization.	  This	  is	  important	  because	  it	  emphasizes	  more	  creative,	  contextualized	  solutions	  that	  fit	  the	  phenotype	  of	  the	  local	  system	  rather	  than	  forcing	  strategies	  that	  have	  been	  designed	  for	  and	  tested	  only	  in	  settings	  with	  more	  resources.	  	  Continued	  monitoring	  of	  these	  projects	  is	  important,	  however.	  	  While	  key	  health	  indicators	  such	  as	  under-­‐five	  mortality	  rates	  are	  improving,	  there	  can	  be	  unintended	  negative	  consequences	  of	  educational	  programs.	  	  For	  example,	  as	  health	  providers	  are	  trained,	  they	  may	  see	  greater	  opportunity	  in	  leaving	  the	  public	  sector	  to	  work	  in	  the	  urban	  private	  sector.	  	  Without	  appropriate	  human	  resources	  planning	  and	  incentives,	  this	  can	  result	  in	  a	  failure	  to	  meet	  the	  underlying	  healthcare	  needs	  of	  underserved	  populations.	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Note	  that	  this	  combination-­‐dosing	  regimen	  need	  not	  be	  dependent	  on	  long-­‐term	  donor	  support	  of	  financing	  or	  human	  resources.	  	  Rather,	  if	  outside	  agencies	  collaborate	  with	  local	  leadership	  to	  employ	  a	  systemic	  capacity	  building	  perspective	  –	  focusing	  not	  just	  on	  training	  of	  individuals	  but	  also	  on	  resourcing	  a	  healthcare	  infrastructure	  that	  rewards	  good	  performance,	  the	  treatment	  may	  exhibit	  a	  post	  antibiotic	  effect	  (PAE)	  such	  as	  that	  described	  with	  aminoglycosides.	  	  During	  this	  window,	  local	  efforts	  to	  create	  robust	  systems	  through	  scaling	  up	  and	  skilling	  up	  health	  providers	  from	  a	  variety	  of	  cadres	  must	  be	  prioritized.	  This	  will	  ensure	  that	  sufficient	  quantities	  of	  highly	  qualified	  staff	  will	  be	  able	  to	  work	  in	  systems	  that	  are	  resourced	  and	  incentivized	  to	  be	  successful	  while	  ensuring	  the	  population	  will	  be	  protected	  against	  future	  emerging	  threats.	  	  	  
Clinical	  pharmacologists	  analyze	  how	  medications	  are	  liberated,	  absorbed,	  distributed,	  metabolized,	  and	  excreted.	  They	  also	  estimate	  total	  drug	  exposure	  over	  time	  to	  minimize	  toxicities	  and	  maximize	  positive	  effects.	  These	  same	  principles	  predict	  the	  potential	  for	  combination	  approaches	  in	  addressing	  emerging	  infections	  through	  health	  systems	  strengthening.	  	  This	  enduring	  approach	  includes	  focused	  investment	  during	  crises	  in	  order	  to	  address	  the	  immediate	  need	  with	  a	  portion	  of	  that	  support	  set	  aside	  to	  build	  functionalities	  in	  the	  system	  in	  order	  to	  sustain	  the	  gains	  in	  the	  response	  to	  these	  diseases.	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Figure	  1:	  Reactive	  responses	  to	  select	  emerging	  and	  reemerging	  epidemics	  	  
Figure	  2:	  The	  kinetic/dynamic	  model	  of	  development	  assistance	  in	  response	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Recognition	  	  of	  emerging	  infectious	  	  disease	  epidemic	  
Infusion:	  	  Continued	  support	  to	  transition	  	  to	  steady	  state	  through	  building	  locally	  sustained	  systems	  	  
Bolus:	  	  Initial	  injection	  of	  support	  to	  address	  urgent	  needs	  
Dashed	  line	  –	  Diminution;	  	  premature	  withdrawal	  of	  	  support	  leads	  to	  a	  rapid	  decline	  in	  effect	  	  of	  realized	  health	  benefits	  	  
Dotted	  line	  –	  Steady	  state;	  	  sum	  of	  all	  parts	  is	  a	  locally	  supported	  system	  responsive	  to	  current	  needs	  and	  future	  health	  threats	  despite	  withdrawal	  of	  outside	  support	  	  
Desired	  therapeutic	  	  range	  
